Streetbeat News

ABOS

Acumen Pharmaceuticals, Inc.

https://acumenpharm.com

Industry

Biotechnology

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Open

1.73

Mkt cap

99M

Volume

169K

High

1.74

P/E Ratio

-1.20

52-wk high

5.09

Low

1.65

Div yield

N/A

52-wk low

1.53

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) held its Q3 2024 earnings call on November 12, 2024. Key company participants included Alex Braun, Dan O'Connell, Matt Zuga, Dr. Jim Doherty, and Dr. Eric Siemers. The call featured questions from analysts at Stifel, BTIG, BofA Securities, and Cantor Fitzgerald.

Portfolio Pulse from

November 12, 2024 | 6:30 pm

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) will participate in a fireside chat at the Stifel Healthcare Conference on November 18, 2024. The company is focused on developing treatments for Alzheimer's disease.

Portfolio Pulse from

November 11, 2024 | 9:15 pm

Acumen Pharmaceuticals has presented promising results from Phase 2 of its clinical trial for the Alzheimer screening drug Sabirnetug. This development could have significant implications for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 12:14 pm

Acumen Pharmaceuticals will present a late-breaking presentation at the 17th Annual Clinical Trials on Alzheimer's Disease Conference. The presentation will focus on the use of a validated pTau217 assay in the participant screening process for their Phase 2 ALTITUDE-AD study of sabirnetug for early Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

October 23, 2024 | 12:13 pm

HC Wainwright & Co. has reiterated its Buy rating on Acumen Pharmaceuticals, maintaining a price target of $15. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 11:28 am

Acumen Pharmaceuticals has extended its collaboration with Lonza to include drug product manufacturing for sabirnetug, a treatment for early Alzheimer's disease. This extension supports potential commercial supply and builds on their existing partnership for drug substance manufacturing.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:18 pm

UBS analyst Colin Bristow maintains a Buy rating on Acumen Pharmaceuticals (NASDAQ:ABOS) but lowers the price target from $14 to $6.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 1:11 pm

Acument Pharmaceuticals shares are trading lower following worse-than-expected Q2 EPS results reported yesterday.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 3:57 pm

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Acumen Pharmaceuticals (NASDAQ:ABOS) and maintained a $15 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 10:33 am

Acumen Pharmaceuticals (NASDAQ:ABOS) reported a Q2 2024 GAAP EPS of $(0.34), missing the analyst consensus estimate of $(0.28) by 21.43%.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:04 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.